Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qurient Co. Ltd.

www.qurient.com

Latest From Qurient Co. Ltd.

US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle

South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.

South Korea United States

KDDF’s Support Reflected In Robust R&D, Licensing By Korean Firms

Various government support schemes seem to have led to recent successful new drug development activities and licensing deals by South Korean pharma and biotech firms. The state-run Korea Drug Development Fund is seen as having played a key role in this effort, providing assistance to 153 R&D programs in the country so far to speed up development of novel and innovative global medicines.

Research & Development South Korea

Bridge Bio Eyes Faster Pipeline Progress Through New Funds, Model

A Series A funding for South Korean bioventure Bridge Biotherapeutics may encourage creation of “no research, development only” bioventures and early investments in the biotech sector.

BioPharmaceutical Asia Pacific

Korean Biotechs Relaunching IPOs After Withdrawals Last Year

South Korean companies that withdrew IPO plans late last year due largely to the crowded year-end offering market are now returning. Among them are drug developers Anterogen and Qurient, which successfully relaunched floats in the second-tier Kosdaq market in February.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Quro Science Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Qurient Co. Ltd.
  • Senior Management
  • Kiyean Nam, PhD, CEO
  • Contact Info
  • Qurient Co. Ltd.
    Phone: 31 8060 1600
    C-dong 8th Floor, 242, Pangyo-ro
    Bundang-gu
    Gyeonggi-do, 463-400
    South Korea
UsernamePublicRestriction

Register